BrainNet Europe's Code of Conduct for brain banking by Klioueva, NM et al.
NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - ORIGINAL ARTICLE
BrainNet Europe’s Code of Conduct for brain banking
Natasja M. Klioueva • Marleen C. Rademaker • David T. Dexter •
Safa Al-Sarraj • Danielle Seilhean • Nathalie Streichenberger • Peer Schmitz •
Jeanne E. Bell • James W. Ironside • Thomas Arzberger • Inge Huitinga
Received: 22 September 2014 / Accepted: 16 December 2014 / Published online: 13 January 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Research utilizing human tissue and its removal
at post-mortem has given rise to many controversies in the
media and posed many dilemmas in the fields of law and
ethics. The law often lacks clear instructions and unam-
biguous guidelines. The absence of a harmonized interna-
tional legislation with regard to post-mortem medical
procedures and donation of tissue and organs contributes to
the complexity of the issue. Therefore, within the BrainNet
Europe (BNE) consortium, a consortium of 19 European
brain banks, we drafted an ethical Code of Conduct for
brain banking that covers basic legal rules and bioethical
principles involved in brain banking. Sources include laws,
regulations and guidelines (Declarations, Conventions,
Recommendations, Guidelines and Directives) issued by
international key organizations, such as the Council of
Europe, European Commission, World Medical Associa-
tion and World Health Organization. The Code of Conduct
addresses fundamental topics as the rights of the persons
donating their tissue, the obligations of the brain bank with
regard to respect and observance of such rights, informed
consent, confidentiality, protection of personal data, col-
lections of human biological material and their manage-
ment, and transparency and accountability within the
organization of a brain bank. The Code of Conduct for
brain banking is being adopted by the BNE network prior
to being enshrined in official legislation for brain banking
in Europe and beyond.
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Introduction
Neurological and psychiatric diseases put a high toll on
public and personal health and cause a heavy economic
burden (Wittchen et al. 2011; Smith 2011). The patholog-
ical processes involved in neurological diseases such as
Alzheimer’s and Parkinson’s disease are now becoming
better understood. However, effective treatments and pre-
vention measures are yet to be identified (Montine et al.
2012). In psychiatric diseases, the nature of molecular and
cellular changes of the brain is still obscure (Deep-Sobo-
slay et al. 2011). Notwithstanding recent impressive pro-
gress in MRI, genetic and biomarker studies as well as
experimental animal research, validation by histological,
cellular and molecular research of the human brain is still
required (Lin et al. 2011). State of the art imaging tech-
niques, genomics and proteomics make human brain tissue
research more compelling than ever. However, CNS tissue
samples can generally only be obtained after death and to
foster research in human brain diseases, brain banks have
been established worldwide (Kretzschmar 2009, Samar-
asekera et al. 2013).
Post-mortem removal and storage of human organs,
research with human brain tissue and genetic research have
often been the centre of media attention (Burton et al.
2003) and posed a great deal of questions in the fields of
law and ethics (Andrews 2006; Case Law 1988; Greenfield
2006). Due to the relative novelty of the Brain Bank as an
entity, the law is often lacking in clear instructions or
specific guidelines. Frequently, brain banks do not fit into
well-defined and harmonized legal regimes while existing
local legal regimes applicable to donation and use of
human organs and tissues for research purposes differ
significantly between countries. Therefore, many uncer-
tainties arise pertaining to initiation and governance of the
brain banks, informed consent, donor confidentiality or
tissue commercialization, which hampers the establishment
of the valuable resources (Bell et al. 2008).
The development of the Code of Conduct for brain
banking and its foundations
The partners of the Brain Net Europe (BNE) consortium, a
consortium of 19 European brain banks, belong to a variety
of academic and/or health institutions, established in ele-
ven different European countries. All of the BNE Brain
Banks are either affiliated with or are part of
(neuro)pathology departments or neuroscience institutes.
Considerable variations in practice, policies and legal
requirements are inevitable. The lack of harmonization in
European legislation with regard to post-mortem medical
procedures and donations of tissue to a biobank for
research purposes contributes to the complexity of the field.
Although a set of uniform exhaustive operating require-
ments was deemed unfeasible to formulate and perhaps in
many cases undesirable to impose, we reasoned that a
certain set of minimum ethical standards had to be main-
tained at all times, regardless of the differences among the
brain banks. To formulate these standards, we systemati-
cally surveyed various authoritative sources in the disci-
plines of law and ethics. These include Declarations,
Conventions, Recommendations, Guidelines and Direc-
tives issued by the international governmental and non-
governmental organizations, such as the Council of Eur-
ope, European Commission, World Medical Association
and World Health Organization (documents used in the
preparation of the Code of Conduct see: http://www.brain
net-europe.org/index.php?option=com_content&view=arti
cle&id=104&Itemid=104%29, http://www.brainbank.nl).
Specifically, the Recommendation on Research on
Biological Materials of Human origin adopted by the
Committee of Ministers of the Council of Europe was
important in the design of the Code of Conduct and func-
tioned as a template for its first draft. To establish a
common ground as well as fundamental differences in the
practices and the legal frameworks under which brain
banks operate, and to involve more BNE members in the
development of the first drafts of the code of conduct, a
meeting in Amsterdam was organized in November 2006.
During this meeting, attendees from different BNE brain
banks have deliberated on principal points to be included in
the code of conduct, thereby setting a certain course. The
first draft of the Code of Conduct was presented during a
BNE meeting in Stockholm, in June 2007. The discussions
during this meeting had mainly revolved around the
requirement for informed consent. Although it had been
established that informed consent of the donor or the next
of kin is not always prescribed by law for conducting an
autopsy and retaining whole organs or tissue samples for
examination or research purposes, the BNE members
agreed that a brain bank should strive to implement the
information and consent procedure in their daily practice
(Lunetta et al. 2007; Sakr et al. 1989). By this ‘‘declaration
of intention’’ in the code of conduct, an aim for a future
standard had been set. Following this meeting, the final
draft of the Code of Conduct has been circulated among all
BNE members with a possibility to comment on its con-
tents and suggest textual amendments. During the next
meeting in Barcelona in June 2008, the final version of the
Code of Conduct was ratified by all BNE brain banks.
Subsequently, at an International Conference on Brain
Banking, organized by the BNE network, in Munich in
December 2008 (http://www.brainnet-europe.org/index.
php?option=com_content&view=article&id=125&Itemid=
141), a workshop on legal and ethical issues in Brain
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Banking was held where the applicability of the Code of
Conduct was discussed. This workshop was attended by the
directors of Brain Banks, scientists as well as representa-
tives of patient organizations from many different coun-
tries. Practical examples of Code of Conduct application in
daily practice were discussed.
The contents of the Code of Conduct and its purpose
The Code of Conduct consists of four Chapters (for the text
of BNE’s Code of Conduct for brain banking see supple-
mentary material). The first Chapter sets out the objectives,
general principles and the scope of the Code of Conduct, as
well as defining key terminology (indicated in the text by
Capital Letters). The second Chapter deals with different
aspects of Material procurement (e.g. Informed Consent,
Authorization, Incompetent persons, Autopsy). The third
Chapter states the principles that should govern the pro-
cessing of the Material (e.g. financial aspects, confidenti-
ality, data protection measures). The fourth Chapter is
concerned with distribution and the use of the Material for
research. It also contains articles on research results and
guidelines on how to deal with information on hereditary
diseases.
The Code of Conduct for brain banking states the
principles that should govern brain banking in general.
Detailed regulations concerning the local governance of a
Brain Bank are to be laid down in a different document
such as a Brain Bank Regulations, which should be in
concordance with the principles described in the code of
conduct. Furthermore to support the daily practice of the
Brain Bank documents such as a Material Transfer
Agreements, Confidentiality Agreements, Tissue applica-
tion forms and Personal Data Protection measures should
be in place. Examples of these documents are provided on
the BNE website (http://www.brainnet-europe.org/index.
php?option=com_content&view=article&id=103&Itemid=
103). The scope of the Code of Conduct could be widened
to cover all post-mortem tissue donations for research
purposes, whether of CNS origin or not (for instance
peripheral lymph nodes or dorsal root ganglia), since the
same principles apply.
Conclusion
BNE’s Code of Conduct is being adopted by the BNE
network prior to being enshrined in official legislation.
BNE has no legal power to enforce it. However, this Code
of Conduct is a first common European attempt to define
ethical standards in Brain Banking in one document. In
case of BNE, the Code of Conduct has stimulated the BNE
brain banks to reflect on their daily practice and on the
governance of their brain banks. We hope that brain
banking will receive more attention in future legislation,
locally and internationally, and that this Code of Conduct
may lay in part a foundation for more official legislation for
brain banking in Europe and beyond.
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